Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Rachel M, Layman"'
Publikováno v:
Breast, Vol 69, Iss , Pp 375-381 (2023)
Background: Palbociclib, the first available cyclin-dependent kinase 4/6 inhibitor, plus endocrine therapy is approved for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (MBC). This
Externí odkaz:
https://doaj.org/article/1760d8d1336f40408af6483302b80b8e
Autor:
Jason A. Mouabbi, Akshara Singareeka Raghavendra, Roland L. Bassett, Amy Hassan, Debu Tripathy, Rachel M. Layman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract The addition of targeted therapies (TT) to endocrine therapy (ET) has improved the outcomes of patients with HR-positive, HER2-negative metastatic breast cancer (mBC). However, it is unknown whether patients with invasive lobular carcinoma (
Externí odkaz:
https://doaj.org/article/982f3e9cb56b48ee9ecd4add8542b9a0
Autor:
Kelsey L. Corrigan, Ramez Kouzy, Joseph Abi Jaoude, Roshal R. Patel, Rachel M. Layman, Sharon H. Giordano, Wendy A. Woodward, Benjamin D. Smith, Simona F. Shaitelman, Ethan B. Ludmir
Publikováno v:
Breast, Vol 66, Iss , Pp 204-207 (2022)
Background: Patients with premenopausal breast cancer (PMBC) have been historically excluded from some clinical trials because of the limitations of using endocrine therapy (ET) in this population. We analyzed breast cancer randomized clinical trials
Externí odkaz:
https://doaj.org/article/6f2801ee8ebb4a3b83372f35df299c04
Autor:
Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-13 (2022)
Abstract Data on real-world effectiveness of cyclin-dependent kinase 4/6 inhibitor combination therapy versus endocrine therapy alone are limited. The Flatiron Health Analytic Database was used to assess overall survival (OS) in patients with hormone
Externí odkaz:
https://doaj.org/article/532b070bf1404214b28d22f57d839c91
Autor:
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Hope S. Rugo
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundElderly patients are generally underrepresented in oncology clinical trials; therefore, real-world data are needed to inform clinical management of elderly patients with hormone receptor–positive/human epidermal growth factor receptor 2
Externí odkaz:
https://doaj.org/article/e1bd7ccab11141abb188b9e3f60b8819
Autor:
Rachel M. Layman, Heather Lin, Angelica M. Gutierrez Barrera, Meghan S. Karuturi, Clinton Yam, Banu K. Arun
Publikováno v:
Cancer Medicine, Vol 11, Iss 6, Pp 1474-1483 (2022)
Abstract Background BRCA‐associated breast cancers tend to have distinctive features compared to sporadic breast cancers; further characterization can aid in optimizing treatment. Methods The study evaluated a patient cohort with early‐stage estr
Externí odkaz:
https://doaj.org/article/d4ac527a527d4079b8d553509d3f7582
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCyclin-dependent kinase 4/6 inhibitors are a standard treatment for patients with hormone receptor−positive (HR+)/human epidermal growth factor receptor 2−negative (HER2−) metastatic breast cancer (MBC). However, real-world data on ef
Externí odkaz:
https://doaj.org/article/ad5cffb6e1d8458096a01ecd1cd72959
Autor:
Angela DeMichele, Massimo Cristofanilli, Adam Brufsky, Xianchen Liu, Jack Mardekian, Lynn McRoy, Rachel M. Layman, Birol Emir, Mylin A. Torres, Hope S. Rugo, Richard S. Finn
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-10 (2021)
Abstract Background Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on
Externí odkaz:
https://doaj.org/article/ffd7b19aa36e4377b6f02a192829a6e4
Autor:
Robert Wesolowski, Andrew Stiff, Dionisia Quiroga, Christopher McQuinn, Zaibo Li, Hiroaki Nitta, Himanshu Savardekar, Brooke Benner, Bhuvaneswari Ramaswamy, Maryam Lustberg, Rachel M. Layman, Erin Macrae, Mahmoud Kassem, Nicole Williams, Sagar Sardesai, Jeffrey VanDeusen, Daniel Stover, Mathew Cherian, Thomas A. Mace, Lianbo Yu, Megan Duggan, William E. Carson
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background While combinations of immune checkpoint (ICP) inhibitors and neo-adjuvant chemotherapy (NAC) have begun testing in patients with breast cancer (BC), the effects of chemotherapy on ICP expression in circulating T cells and within t
Externí odkaz:
https://doaj.org/article/70fdc2b010ae46fe8b7001ba65aea064
Autor:
Toshiaki Iwase, Kenichi Harano, Hiroko Masuda, Kumiko Kida, Kenneth R. Hess, Ying Wang, Luc Dirix, Steven J. Van Laere, Anthony Lucci, Savitri Krishnamurthy, Wendy A. Woodward, Rachel M. Layman, François Bertucci, Naoto T. Ueno
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background The purpose of this study was to determine the prognostic role of hormone receptor (HR) on inflammatory breast cancer (IBC) to elucidate its aggressive biological behavior. Methods We evaluated the expression of estrogen receptor
Externí odkaz:
https://doaj.org/article/e7df9ce540224a8793e5c2239b2fe831